Engineering human stellate cells for beta cell replacement therapy promotes in vivo recruitment of regulatory T cells.

Engineering human stellate cells for beta cell replacement therapy promotes in vivo recruitment of regulatory T cells.

Type 1 diabetes (T1D) is an autoimmune illness characterised by destruction of pancreatic β cells. One of the promising therapeutic approaches in T1D is the transplantation of islets; nevertheless, it has critical limitations. To tackle these limitations, immunotherapeutic methods have targeted on restoring immunologic tolerance, stopping transplanted cell destruction by sufferers’ personal immune system. Macrophage-derived … Read more